Tissue Therapies Limited is a biomedical technology company that is developing significantly more effective treatments for acute and chronic wound healing applications, including chronic skin ulcers and burns. Tissue Therapies Limited is commercialising VitroGro® ECM, a technology created by cell biology, tissue engineering and protein engineering experts at the Institute of Health and Biomedical Innovation at the Queensland University of Technology. The company is also developing treatments for psoriasis, scar prevention and various cancers including those of the breast, colon and prostate.
VitroGro® ECM is a sterile, acellular biomimetic scaffold for the treatment of hard-to-heal wounds, primarily venous leg ulcers. VitroGro® ECM replaces degraded wound matrix. VitroGro® ECM binds to a prepared wound bed and provides a scaffold for cell attachment, which is a primary requirement for subsequent cell functions critical for healing, such as, cell proliferation and migration. VitroGro® ECM improves wound closure and reduces pain thereby improving wound care.